RG
MEDP icon

Renaissance Group’s Medpace MEDP Stock Holding History

Renaissance Group’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83M Sell
16,664
-7,830
-32% -$3.61M 0.36% 78
2026
Q1 		$11.8M Buy
24,494
+4,452
+22% +$2.28M 0.49% 60
2025
Q4 		$11.3M Buy
20,042
+116
+0.6% +$65.8K 0.45% 57
2025
Q3 		$10.2M Buy
19,926
+1,577
+9% +$689K 0.39% 66
2025
Q2 		$5.76M Buy
18,349
+4,259
+30% +$1.28M 0.22% 112
2025
Q1 		$4.29M Buy
14,090
+2,567
+22% +$863K 0.19% 113
2024
Q4 		$3.83M Buy
11,523
+1,168
+11% +$396K 0.16% 115
2024
Q3 		$3.46M Buy
10,355
+56
+0.5% +$21.3K 0.14% 116
2024
Q2 		$4.24M Sell
10,299
-712
-6% -$282K 0.17% 110
2024
Q1 		$4.45M Buy
11,011
+2,025
+23% +$712K 0.17% 109
2023
Q4 		$2.76M Sell
8,986
-563
-6% -$152K 0.11% 128
2023
Q3 		$2.31M Buy
9,549
+113
+1% +$28.9K 0.11% 124
2023
Q2 		$2.27M Buy
9,436
+534
+6% +$111K 0.1% 127
2023
Q1 		$1.67M Buy
8,902
+574
+7% +$119K 0.08% 164
2022
Q4 		$1.77M Buy
8,328
+125
+2% +$25K 0.09% 119
2022
Q3 		$1.29M Buy
8,203
+266
+3% +$42.4K 0.07% 152
2022
Q2 		$1.19M Buy
7,937
+392
+5% +$56.7K 0.06% 161
2022
Q1 		$1.23M Buy
7,545
+388
+5% +$64K 0.06% 160
2021
Q4 		$1.56M Buy
7,157
+310
+5% +$64.9K 0.06% 129
2021
Q3 		$1.3M Sell
6,847
-96
-1% -$17.5K 0.06% 131
2021
Q2 		$1.23M Sell
6,943
-1,170
-14% -$202K 0.05% 141
2021
Q1 		$1.33M Buy
8,113
+262
+3% +$40.1K 0.06% 124
2020
Q4 		$1.09M Buy
7,851
+38
+0.5% +$4.79K 0.05% 135
2020
Q3 		$873K Buy
7,813
+38
+0.5% +$4.39K 0.04% 133
2020
Q2 		$723K Sell
7,775
-68
-0.9% -$5.79K 0.03% 159
2020
Q1 		$576K Sell
7,843
-1,343
-15% -$117K 0.03% 176
2019
Q4 		$772K Buy
9,186
+3,440
+60% +$266K 0.03% 171
2019
Q3 		$483K Sell
5,746
-3,113
-35% -$235K 0.02% 203
2019
Q2 		$580K Buy
+8,859
New +$511K 0.02% 182

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Group's MEDP Position: Q2 2026 in Review

Renaissance Group reduced its Medpace (MEDP) stake by 32% in Q2 2026, selling an estimated $3.61M and leaving 16,664 shares worth $8.83M. The position accounts for 0.36% of the portfolio, ranked #78.

Renaissance Group first reported a position in MEDP in Q2 2019 and has held it in 29 quarters since. The position peaked at $11.8M in Q1 2026. 695 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Renaissance Group held 16,664 shares of Medpace worth $8.83M as of Q2 2026.
  • Renaissance Group sold 7,830 Medpace shares in Q2 2026, an estimated $3.61M.
  • Medpace made up 0.36% of Renaissance Group's portfolio in Q2 2026, its #78 holding.
  • Renaissance Group first reported a position in Medpace in Q2 2019 and has held it in 29 quarters since.
  • Renaissance Group's Medpace position peaked at $11.8M in Q1 2026.
  • 695 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.